Gallbladder carcinoma (GBC) remains one of the most lethal cancers of the biliary tract, with late‑stage diagnosis, limited treatment options and poor survival rates. New research consolidates evidence that microRNAs (miRNAs) function as powerful post‑transcriptional regulators of gene expression and could reshape both prognostic assessment and therapeutic strategies for this disease.
Epidemiology and current clinical challenges
Worldwide, GBC affects roughly 2.3 per 100,000 people, accounting for 1.2% of all cancer diagnoses and 1.7% of cancer deaths. According to GLOBOCAN 2022 data that separate GBC from cholangiocarcinoma, the disease generates 122,491 new cases and 89,055 deaths each year, ranking it the 22nd most common cancer and the 17th deadliest malignancy globally. The gallbladder, a small cystic organ beneath the liver that stores and concentrates bile, can develop malignancy through a cascade that begins with chronic inflammation, gallstones, obesity, viral hepatitis, heavy‑metal exposure, genetic predisposition and anatomical abnormalities. These risk factors drive metaplastic changes that progress from dysplasia to carcinoma in situ and ultimately invasive carcinoma.
Because the disease often progresses without symptoms, most patients are diagnosed at advanced stages. Survival data illustrate the stark contrast: five‑year survival exceeds 90% for Stage I disease but falls to about 30% for Stage III and IV, based on AJCC/UICC staging criteria. Surgical resection remains the sole curative option, underscoring the urgent need for reliable early‑diagnostic biomarkers and novel therapeutic targets.
MicroRNAs as emerging biomarkers
MicroRNAs are short, approximately 22‑nucleotide, non‑coding RNA molecules transcribed from DNA into hairpin precursors. They regulate gene expression by binding to the 3′‑untranslated region of target messenger RNAs, thereby inhibiting translation or promoting degradation. In GBC, several miRNAs have been repeatedly implicated across retrospective human tissue studies, in‑vitro cell‑culture experiments and animal models.
The review highlights five miRNAs with the strongest evidence base: miRNA‑155, miRNA‑146b‑5p, miRNA‑141, miRNA‑195‑5p and miRNA‑335. miRNA‑155 is frequently documented in retrospective human tissue cohorts as a prognostic marker. miRNA‑146b‑5p has been examined both in cell‑culture models and tissue cohorts, emerging as a prognostic biomarker and a potential therapeutic target; functional assays show it can induce apoptosis and cause G1‑phase cell‑cycle arrest, thereby inhibiting tumor progression. miRNA‑141, a member of the miRNA‑200 family, has been linked to regulation of epithelial‑mesenchymal transition (EMT) and cell proliferation in multiple cancers, and its expression correlates with prognostic outcomes in GBC. miRNA‑195‑5p demonstrates therapeutic potential by suppressing oncogenic signaling pathways, notably the Wnt/β‑catenin cascade, while miRNA‑335 has been associated with chemoresistance and prognostic value in clinical studies.
Additional miRNAs are noted for their mechanistic relevance. miRNA‑21 suppresses the tumor‑suppressor PTEN, thereby promoting proliferation, migration and invasion in GBC cells. Conversely, miRNA‑145‑5p is down‑regulated in tumor tissue; its restoration activates direct and indirect targets of signal transducer and activator of transcription 1 (STAT1), suggesting a tumor‑suppressive role.
Pathway modulation and therapeutic implications
MicroRNAs influence several key signaling pathways that drive GBC pathogenesis. The PI3K/AKT pathway, the Wnt/β‑catenin axis, epidermal growth factor receptor (EGFR) signaling and the JAK/STAT cascade are all modulated by specific miRNAs. For instance, miRNA‑21’s inhibition of PTEN leads to hyper‑activation of the PI3K/AKT pathway, while miRNA‑195‑5p’s suppression of Wnt/β‑catenin signaling curtails tumor growth. Constitutive activation of STAT3 has been reported in GBC and correlates with advanced disease stage and poor prognosis, positioning STAT3‑targeting miRNAs as attractive candidates for future interventions.
The functional impact of miRNA‑146b‑5p—inducing apoptosis and G1 arrest—exemplifies how miRNA manipulation could translate into therapeutic benefit. By restoring or mimicking tumor‑suppressive miRNAs, or by inhibiting oncogenic miRNAs such as miRNA‑21, researchers aim to disrupt the molecular circuitry that sustains malignancy.
Beyond their mechanistic roles, miRNAs hold promise as non‑invasive biomarkers. Their stability in circulation allows detection in blood samples, offering a potential route for early diagnosis and monitoring of treatment response. However, the review notes a persistent gap in clinically validated early‑diagnostic tools for GBC, emphasizing the need for further translational research.
Historical context of biomarkers
The concept of a biomarker has evolved over decades. The term “biochemical marker” appeared in 1949, while “biological marker” was introduced in 1957. A formal definition emerged in 1973, describing biomarkers as the presence or absence of biological material. In 2000, the National Institutes of Health (NIH) Biomarkers Definitions Working Group provided a widely accepted definition for clinical pharmacology, and the U.S. Food and Drug Administration (FDA) later categorized biomarkers into diagnostic, prognostic, predictive, safety and monitoring groups. Within this framework, miRNAs are positioned as diagnostic and prognostic biomarkers that can inform disease presence, progression and therapeutic response.
Collectively, the evidence underscores a shift toward molecularly guided management of gallbladder carcinoma. By integrating miRNA profiling into clinical workflows, physicians may soon achieve earlier detection, more accurate prognostication and personalized therapeutic regimens that move beyond the current reliance on surgical resection alone.
Continued investigation into the five highlighted miRNAs—miRNA‑155, miRNA‑146b‑5p, miRNA‑141, miRNA‑195‑5p and miRNA‑335—along with broader miRNA panels, is essential to bridge the existing diagnostic gap and to develop targeted therapies that could improve survival for patients confronting this aggressive cancer.






Be First to Comment